MicroRNA Regulation of Human Genes Essential for Influenza A (H7N9) Replication

Influenza A viruses are important pathogens of humans and animals. While seasonal influenza viruses infect humans every year, occasionally animal-origin viruses emerge to cause pandemics with significantly higher morbidity and mortality rates. In March 2013, the public health authorities of China reported three cases of laboratory confirmed human infection with avian influenza A (H7N9) virus, and subsequently there have been many cases reported across South East Asia and recently in North America. Most patients experience severe respiratory illness, and morbidity with mortality rates near 40%. No vaccine is currently available and the use of antivirals is complicated due the frequent emergence of drug resistant strains. Thus, there is an imminent need to identify new drug targets for therapeutic intervention. In the current study, a high-throughput screening (HTS) assay was performed using microRNA (miRNA) inhibitors to identify new host miRNA targets that reduce influenza H7N9 replication in human respiratory (A549) cells. Validation studies lead to a top hit, hsa-miR-664a-3p, that had potent antiviral effects in reducing H7N9 replication (TCID50 titers) by two logs. In silico pathway analysis revealed that this microRNA targeted the LIF and NEK7 genes with effects on pro-inflammatory factors. In follow up studies using siRNAs, anti-viral properties were shown for LIF. Furthermore, inhibition of hsa-miR-664a-3p also reduced virus replication of pandemic influenza A strains H1N1 and H3N2.


Introduction
Influenza virus is still a serious global health threat affecting humans, wildlife and agricultural species. Human infection with avian influenza A H7N9 virus (H7N9) were first reported in China in March 2013 [1] Most of the infections are believed to have resulted from exposure to infected poultry or contaminated environments, as H7N9 viruses have been found in poultry in China. While some mild illnesses in humans infected with H7N9 has been reported, most patients experienced severe respiratory illness, such as pneumonia (97.3%) and acute respiratory distress syndrome (71.2%), leading to high rates of intensive care unit admissions [2]. Human mortality attributed to influenza H7N9 is over 38% with 175 deaths from 450 confirmed cases within a 20-month period [3]. No evidence of sustained human-to-human transmission of H7N9 has been recorded; however, there was some evidence for limited person-to person spread under rare circumstances [4]. H7N9 began in China, but now has rapidly spread to other countries [5]. Recently, the first documented case of H7N9 in humans was reported for North America in Canada [6] No vaccine is currently available for H7N9 [7]. There are several drugs available for the treatment of influenza infections including the M2 ion channel inhibitors amantadine and rimantadine, and the neuraminidase inhibitors, zanamivir and oseltamivir [8,9]. Early treatment with these antiviral drugs has been shown to reduce the duration of symptoms and time to recovery, however, the use of antiviral drugs is complicated by the emergence of drug resistant viruses [10,11]. Consequently, oseltamivir-resistant H7N9 strains have already been described in recent reports from Taiwan [12]. In addition, the use of antiviral drugs may have an effect on population vulnerability due to lack of seroconversion, as well as driving drug resistance among circulating strains [13]. To prevent the spread of infection, new drug and vaccine development is needed. However, difficulties include a lack of understanding of the host factors required for replication, and unusual mutations that occur in the virus that differ from other avian influenza viruses [14].
Linking high-throughput screening (HTS) with RNA interference (RNAi) allows for the rapid discovery of the molecular basis of disease pathogenesis, and the identification of potential pathways for the development of safe and effective treatments. Recent advances in our understanding of RNAi have allowed for genome-wide screens to determine and validate the host cell genes that may are required for influenza virus replication [15] Small interfering RNA (siRNA) can be readily developed to target viral or host genes, and have been successfully applied in disease intervention approaches. For example, siRNA targeting respiratory syncytial virus has been efficacious for silencing virus replication [16]. In the case of influenza, inhibiting the host gene CAMK2B prevented virus replication in vitro [17], and knocking down trypsin also inhibited virus replication and apoptosis [18]. In a siRNA screen of 481 human protease genes in A549 cells, 5 genes, ADAMTS7, CPE, DPP3, MST1 and PRSS12, were identified as essential for influenza virus replication [19]. Another siRNA screen of 720 human protein kinase genes (HPK), 17 HPKs were validated as essential for influenza A replication [20]. In both screens vital genes for influenza A replication were found that affect multiple host pathways and that are regulated by microRNAs (miRNAs) induced during infection.
In addition to host gene involvement during viral infection, the magnitude and tempo of host gene expression is governed by factors such as miRNA. miRNAs have been used to validate the impact of host genes on virus replication and have been used as therapeutics [21] with the ability to negatively affect influenza replication [22]. Thus, host miRNAs have a role in host gene expression in response to influenza infection. miRNAs are small noncoding singlestranded RNA molecules composed of 18-23 nucleotides which regulate gene expression in eukaryotes. The miRNA family is a global regulatory network controlling homeostasis, inflammatory responses affecting immunity and disease pathogenesis [23]. miRNAs are involved in the degradation of cytokine transcripts and modulate the expression of negative regulators of cytokine expression and signaling pathways [24]. Paired analysis of miRNA inhibitors and mimics enables gain and loss of function studies for a given miRNA. miRNA can not only be used as a tool for screening, but also as a therapeutic itself. The drug miravirsen is an anti-miRNA drug candidate currently in late stage clinical evaluation for treatment of hepatitis C virus (HCV) infections. Miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA [25]. In this study, a genome wide HTS was performed to identify target miRNAs as countermeasures of H7N9 replication. Several proviral host miRNA's were identified which are important for H7N9 replication. In validation studies, the most promising target, hsa-miR-664a-3p (miR-664), was further investigated and the effects on downstream genes, Leukemia inhibitory factor (LIF) and NIMA-related kinase 7 (NEK7), were explored ( Fig 1A).

Results
Genome wide high-throughput screen of miRNAs that govern influenza H7N9 replication A human genome wide HTS was performed in A549 cells using miRNA inhibitors to reveal possible host targets that are important for H7N9 replication. Z-score (the number of standard  deviations from the mean) was used to normalize data to provide explicit information on the strength of each miRNA inhibitor relative to the rest of the sample distribution. A negative zscore reveals inhibitors that decrease virus replication, where a positive z-score reflects miRNA inhibitors that increase virus replication. All miRNAs inhibitors having a z-score lower than -1.50, 29 in total, were investigated ( Fig 1B). Cytotoxicity assays were performed to rule out miRNA inhibitors with a toxic effect on cells (data not shown). Finally, 10 miRNA top hits with the most negative z-scores were identified (Table 1) for validation studies.

Validation of top 10 miRNA inhibitors that reduce influenza A H7N9 replication
To validate the top 10 miRNAs from the HTS, A549 cells were transfected (25 nM) with miRNA inhibitors or mimics, and then infected (MOI 0.01) with H7N9. Supernatants and cell monolayers were processed to investigate virus replication. Cellomics ArrayScan (Thermo-Scientific) was used to count the number of infected cells by using fluorescent viral nucleoprotein (NP)-staining combined with DAPI (4',6-diamidino-2-phenylindole) staining of the nuclei. Approximately 40% of cells were infected in the non-transfected control (NTC) (Fig  2A). Reduction of H7N9 infectivity, as predicted from HTS, was confirmed in validation studies for 8 miRNAs. Inhibition of H7N9 replication by miRNA-664 was confirmed where infectivity of H7N9 was reduced by 27% ( Fig 2B). siNP, which targets the viral nucleoprotein (NP), was used as positve control for the inhibition of H7N9 replication. siNP reduced replication of H7N9 by 63%. Negative controls having minimal sequence identity were used for all miRNA inhibitors and mimics to differentiate between specific and non-specific effects, and the negative transfection controls had no impact on virus replication.
The pro-viral properties of miR-664 were confirmed as the inhibitor of miR-664, miR664i, significantly (p<0.05) reduced virus replication by nearly 2 logs. siNP, as the positive control, significantly (p<0.05) reduced H7N9 replication by 1 log. Negative transfection controls had no impact on virus replication. Together, miR664i revealed the most potent antagonizing effect on H7N9 replication and was therefore selected to investigate downstream events and to perform host pathway analysis. Other potent miRNAs regulating H7N9 replication, e.g. hsa-miR-1244 and hsa-miR-4286, were not further investigated in this study, but is the subject of a burgeoning study.

Identification of miRNA gene targets during influenza A H7N9 infection
To determine whether miR-664 inhibitor, miR664i, targets influenza A (H7N9) or impairs virus replication by affecting the host cell machinery, a BLAST (Basic Local Alignment Search Tool) search was performed to compare miR-664 and H7N9 virus microRNA seed sites. No noteworthy microRNA seed sites in the H7N9 sequence were found (fludb.org), so it is unlikely the miRNA inhibitor is directly targeting viral gene expression. Thus, miR-664 may be a proviral miRNA, required by the virus to downregulate downstream target genes which are important for viral defense mechanisms by the host cell. Pathway analysis using Ingenuity Pathway Analysis (IPA) was used to explore downstream targets of miR-664. A data set was created from the targetscan.org database using the miRNA target scan option in IPA. Since there was no experimental data available for miR-664, results were filtered for targets with highly-predicted confidence for an interaction with miR-664. The IPA target scan produced a pathway for 8 highly predicted targets of miR-664 and their predictive interactions (Fig 3). Pathways of the predicted target genes for miR-664 are not well characterized; however, some are known to have ubiquitous functions in the cell ( Table 2). Specific focus was set on molecules LIF and NEK7. LIF and NEK7 may be linked to regulatory functions in cytokine pathways such as the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-12a and the chemokine CXCL10 (Table 3). Reports from H7N9-infected humans have shown significant upregulation of IL-6 and CXCL10 compared to healthy controls [2,[26][27][28][29]. In a study on mice, IL-6 was shown to be a main driver of lung pathology [30]. An interesting finding was that the expression of IL-12a was upregulated with other avian influenza viruses, but not in cells infected with H7N9 [31]. Therefore, roles of LIF and NEK7 in the pro-viral effect of miR-664 were further investigated.  Regulation of miR-664 expression and host gene targets during Influenza H7N9 infection RT-qPCR was used to investigate the gene expression levels of miR-664 and predicted host target genes, LIF and NEK7, during infection with H7N9. miR-664 was upregulated nearly 10-fold (p<0.05) in A549 cells infected (MOI = 0.1) with H7N9 at 24 h pi (hours post-infection) compared to non-infected A549 cells (Fig 4). Importantly, potential target genes LIF (p<0.01) and NEK7 (p<0.05) were significantly downregulated, indicating a correlation between miR-664 and the target genes predicted by IPA. Follow up studies aimed to investigate whether there was a direct effect of miR-664 inhibitor, miR664i, on the gene expression levels of the target genes during infection with H7N9. A549 cells were transfected with miR664i prior to infection with H7N9. LIF and NEK7 gene expression was downregulated during H7N9 infection compared to non-infected control cells as previously observed (Figs 4 and 5). LIF and NEK7 gene expression levels were rescued when the cells had been transfected with miR664i prior to infection (Fig 5). Thus, miR-664 may have a direct impact on target genes LIF and NE7 and their expression levels during influenza A H7N9 infection.

Target gene knock-down identifies antiviral properties
Small interfering RNAs targeting LIF (siLIF) or NEK7 (siNEK7) were used to investigate the role of target genes LIF and NEK7 on virus replication (Fig 6). A549 cells were transfected  Knocking down NEK7 did not impair virus replication, and thus this target gene may not be a critical factor in defense against influenza A viruses (data not shown). All siRNAs had prior been evaluated for their efficacy in downregulating the specific mRNA by RT-qPCR (S1 Fig).
These results demonstrate that combining HTS and RNAi can lead to the rapid discovery of host cellular targets and the underlying pathways that participate in virus replication.

miR664i reduces the replication of pandemic influenza A strains A/Ca and A/Phi
In order to investigate potential broad-spectrum antiviral effects of miR664i, A549 cells were transfected with miR664i at 25 nM for 48 h and subsequently infected with with A/Ca (H1N1) at MOI 0.1 and A/Phi at MOI 0.05 for 48 h. miR664i reduced both cell infectivity and virus titers for both virus strains investigated (Fig 7) by almost 2 logs TCID 50 . Targeting the host cell machinery to countermeasure influenza A H7N9 helped to discover a miRNA with broad proviral characteristics. Inhibition of miR664 limited the replication of various influenza A strains, including H7N9 and the pandemic H1N1 and H3N2, without putting evolutionary pressure on the virus which could potentially lead to resistant mutations.

Discussion
To our knowledge this is the first report on a miRNA-based antiviral therapeutic that countermeasures H7N9 replication in vitro. miR664i, an inhibitor of host cell miRNA miR-664, showed potent antiviral effects inhibiting H7N9 replication by two logs (TCID 50 titers) in A549 cells. A549 cells are a good proxy to establish and characterize an in vitro model of Type II respiratory alveolar epithelium, and as α2,3-linked or α2,6-linked sialic acids in principle dictate influenza virus susceptibility, A549 cells are highly susceptible to influenza infection and have been widely used as a cell culture model to study influenza A for almost two decades [32]. We anticipate examining the effects of miR664i on influenza A replication in BEAS2B cells or differentiated NHBE cells. In addition, we aim to investigate the antiviral potential of miR664i in animal models. There have been numerous successful attempts to increase potency and stability and to reduce off-target effects of RNAi therapeutics in recent years [33]. Lockednucleid acid (LNA) modification can improve the serum stability, where the design of short hairpin RNA (shRNA) can be used as potent RNAi triggers. Lipid nanoparticles as carriers and adenovirus-mediated RNAi against viral infections have also successfully been applied [34,35].
In vivo studies showed a reduction of hepatitis B virus (HBV) when mice were injected with LNA-modified RNAi therapeutics [36]. The most prominent use of LNA technology is the clinical candidate miravirsen, where monthly subcutaneously application can downregulate miR-122 and subsequently reduce HCV replication [37,38]. In future studies, we will implement some of these techniques to investigate the potential of miR664i to countermeasure influenza A replication in a mouse model. In a recent publication, MIR2911, a broad spectrum antiviral miRNA suppressed replication of H1N1, H5N1 and H7N9 influenza virus in vitro and in vivo [39]. MIR2911 targeted the PB2 and NS1 gene of influenza A, and considerably inhibited their protein expression. However, MIR2911 was ineffective against mutant influenza viruses in which the MIR2911-binding nucleotide sequences were altered. In contrast, miR664i does not target the virus directly and the antiviral effects may be directed through intracellular mechanisms in the host cell. One advantage of targeting the host cell miRNA, instead of the virus directly is the lower probability of the virus evolving mutations that would potentially lead to resistance against the therapeutic. In these studies, which examined mechanisms underlying the antiviral actions of miR664i, upregulation of miR-664 was observed during H7N9 infection of A549 cells. This is in accordance with a previous study investigating the expression of miRNAs in blood serum samples from H7N9-infected patients [40]. There, miR-664 expression was shown to be highly upregulated compared to healthy controls. Further, in a microarray screen of human blood serum from pandemic H1N1-infected patients and of H1N1-infected cell lines, miR-664 has been shown to be upregulated during infection [41]. However, whether the virus directly controls the upregulation of miR-664 in the cell, or if the virus takes advantage of the cells unbeneficial upregulation of miR-664 remains unclear.
The two molecules LIF (leukemia inhibitors factor), and NEK7 (NIMA-related kinase 7), were highly predicted target genes for miR-664based on the targetscan.org database. Gene expression studies showed that while miR-664 was upregulated during H7N9 infection, target genes LIF and NEK7 were downregulated. When miR664i was transfected prior to infection, expression levels of target genes were subsequently normalized. Thus, the inhibitory effect of miR-664 on its target genes during influenza infection may facilitate virus replication (Fig 8). A similar effect has been shown for miR-466I, which inhibits the host antiviral innate immune response against Sendai virus by targeting interferon (IFN)-α expression in vitro [42]. Unlike miR-466, no seed sites for miR-664 can be found in any of the human IFN genes. Therefore, a direct action of miR-664 IFN gene expression is not expected. However, it is possible that miR-664 can regulate virus-induced IFN production and secretion indirectly through other molecules in the IFN induction pathway. Furthermore, ongoing studies also aimed to address whether IFN regulates miR-664 expression in infected and non-infected cells. As these examples suggest, upregulation of specific miRNAs during virus infections can be harmful for the host. Nevertheless, several reports have shown that downregulation of other miRNAs can also result in increased virus replication.
In studies examining the furin-dependent proteolytic activation of highly pathogenic influenza H5 and H7 viruses, the miR-24 response was shown to strongly decrease both furin messenger RNA (mRNA) levels and intracellular furin activity in A549 cells [43]. Cells transfected with miR-24 mimics showed a decrease of H5N1 infectious virions and a complete block of H5N1 virus spread that was not observed in cells infected with H1N1 virus. This suggests that a virus-specific downregulation of furin-directed miRNAs such as miR-24 may represent a viral regulatory mechanism to govern the production of infectious virions.
To investigate the underlying mechanisms of miR-664 during influenza replication, knockdown studies using siRNA targeting LIF and NEK7 were performed. Knocking down NEK7 had no impact on virus replication, which suggests a non-relevant role of this particular kinase during influenza infection However, knocking down LIF increased virus replication in various influenza A strains. This suggests that miR-664 may downregulate LIF, which may be an important factor in immune defense against influenza A. Whether there are other factors involved and what happens downstream of LIF has yet to be determined. The importance of LIF in antiviral defense has been reported in previous publications [44]. In vivo studies were performed with LIF knock-out mice that were infected with RSV. LIF knock-out mice yielded higher virus titers compared to control mice. Furthermore, mice treated with anti-LIF IgG developed enhanced RSV pathology observed with increased airspace protein content, apoptosis and airway hyperresponsiveness compared to control IgG treatment. Thus, LIF may be a critical factor in the antiviral defense against RSV and other respiratory diseases such as influenza A. Whether this is solely mediated by miR-664, or by other mechanisms, remains unknown and will need to be investigated. Furthermore, it remains unclear if virus infection and /or replication initiates the upregulation of miR-664 to avoid the antiviral effects of LIF, or if this mechanism is a non-beneficial reaction by the host cell during virus infection.
In conclusion, the current study reports the discovery of an important pro-viral miRNA that can be targeted by readily available miRNA inhibitor miR664i. The field of miRNA inhibitors is on the rise with many candidates currently being tested in clinical trials. The most clinically advanced example of a miRNA antagonist is the antiviral miravirsen which is currently undergoing multiple clinical phase II studies against Hepatitis C (ClinicalTrials.gov identifier: NCT01200420, NCT02031133, NCT01872936, NCT01727934). Miravirsen targets the conserved host factor miR-122, which stimulates translation of HCV RNA. Thus, miR-122 is a promising target, as it is hoped that the virus would not be able to acquire resistance mutations to miravirsen. The promising antiviral candidate miR664i owns unique characteristics in the novel field of miRNA inhibitors as countermeasures against the potential pandemic and lifethreatening infectious disease caused by H7N9. In addition, miR664i also shows great potential in treating pandemic circulating influenza A strains such as H1N1 and H3N2.

High-throughput miRNA inhibitor transfection screening
The miRNA inhibitor screen was performed in A549 cells as shown in Fig 1A. miRNA inhibitors (Dharmacon, GELifeSciences) were reverse-transfected into A549 cells at a final concentration of 20 nM in 0.3% DharmaFect1 (Dharmacon, GELifeSciences) transfection reagent. Non-targeting miRNA inhibitor controls (Dharmacon, GELifeSciences) were used in all assays as negative controls and siRNAs targeting NP (siNP) was used as positive controls. Briefly, using a 96-well format, miRNA inhibitors were mixed with DharmaFect1 reagent in serumfree medium (Opti-MEM, GELifeSciences) and incubated at room temperature for 20 min. A549 cells were then added at 10,000 cells/well in DMEM supplemented with 10% FBS using Liqudator96 (Mettler Toledo). 48 h post-transfection, the cells were infected with H7N9 in 100 μl of DMEM supplemented with 2% FBS, at a MOI 0.1. 24 h pi, the cells were fixed with methanol acetone (80:20) for 15 min and stored until analysis by ELISA.

ELISA assay
The miRNA primary screen to identify host genes involved in down-regulating H7N9 virus replication in A549 cells was completed using a NP-specific ELISA assay. The fixed cells were incubated with a mouse anti-NP monoclonal antibody (ATCC H16-L10-4R5) at 37°C for 1 h and then incubated with an HRP-conjugated goat anti-mouse secondary (Invitrogen). Afterwards, the plates were washed with PBS followed by 15 min incubation with HRP-substrate solution (SureBlue TMB). H 2 SO 4 stop solution was then added to the plates to terminate the reaction. The plates were scanned with a plate spectrophotometer at a wavelength of 450 nm.
The OD values of experimental wells were normalized to the control wells and converted to a Z-score to create a hierarchical list containing miRNAs in the entire screen according to methods described previously [20]. In this study, all hits with a Z-score -1.5 and cytotoxicity (ToxiLight™ bioassay kit; Lonza) below 5% were subject to further validation in A549 cells.
Validation assays miRNA hairpin inhibitors and mimics and ON-TARGETplus siRNAs (Dharmacon, GE Life-Sciences) were reverse-transfected with 0.3% DharmaFect1 transfection reagent into A549 cells at a final concentration of 25 nM and 50 nM, respectively. Non-targeting miRNA inhibitor controls (Dharmacon, GELifeSciences) were used as negative controls and siRNAs targeting NP (siNP) was used as positive controls. Briefly, using a 96-well format, miRNA inhibitors and mimics and siRNAs were mixed with DharmaFect1 transfection reagent in serum-free medium (HBSS, Invitrogen) and incubated at room temperature for 20 min. A549 cells were then added at 10,000 cells/well in DMEM supplemented with 5% FBS. 48 h post-transfection, the cells were infected with influenza A viruses while the transfection medium was tested for cytotoxicity with a ToxiLight™ bioassay kit (Lonza). miRNA inhibitors and mimics exceeding a toxicity of 5% were excluded for further validation.
48 h pi, the cell monolayers were fixed with 10% buffered formalin and permeabilized with Triton X-100. Cells were stained with a mouse anti-NP monoclonal antibody (ATCC H16-L10-4R5) and subsequently with a secondary Alexa Fluor 488 anti-mouse antibody (Life Technologies) each for 1h at room temperature. Cells were counterstained with DAPI to quantify the number of infected cells with Cellomics ArrayScan (Thermo Scientific). Supernatants were used to determine TCID 50 titers on confluent MDCK cells. 10-fold serial dilutions were added to MDCK cells in a 96-well plate format and incubated for 72 h at 37°C and 5% CO 2 . Supernatants from MDCK cells were then tested for hemagglutination with 0.5% turkey red blood cells. TCID 50 values were calculated using the Spearman Karber method [45,46]. All infections were performed in the presence of 1 μg/mL (L-tosylamido-2-phenyl)ethyl chloromethyl ketone treated (TPCK) trypsin (Worthington Biochemical) in modified Eagle's medium (MEM) supplemented with 0.3% bovine serum albumin (Gibco, Life Technologies).

RNA isolation and qRT-PCR
Total RNA was isolated using TRIzol (Invitrogen Life Technologies). The concentration of total isolated RNA was measured by using a Microplate Spectrophotometer (Epoch, BioTek). qRT-PCR was used to validate mRNA and miRNA expression changes using the Stratagene Mx3005P real-time PCR system (Agilent Technologies). The reverse transcription reactions were performed using a miRNA 1st-Strand cDNA Synthesis Kit (Agilent Technologies) using 500 ng total RNA for each reaction. qRT-PCR was performed using the Brilliant III Ultra-Fast SYBR1 Green QRT-PCR Master Mix (Agilent Technologies) to determine miRNA and mRNA expression, and data were normalized to 18S expression using the 2 -ΔΔCt method. Primer sequence for miR-664 was, 5'-TATTCATTTATCCCCAGCCTACA-3' (forward primer) and a universal reverse primer. Primers sequences for LIF were, 5'-ACAGAGCCTTT GCGTGAAAC-3' (forward primer) and 5'-TGGTCCACACCAGCAGATAA-3' (reverse primer). Primer sequences for NEK7 were, 5'-CACCTGTTCCTCAGTTCCAAC-3' (forward primer) and 5'-CTCCATCCAAGAGACAGGCTG-3' (reverse primer).

Statistical analysis
All experiments were performed in biological triplicates and technical duplicates and have been repeated at least twice. Data are expressed as means ± SEM. Differences between different biological groups were compared by one-way analysis of variance (ANOVA). Individual differences between groups were tested by multiple comparison and analysis using the Tukey posttest. Pairs of groups were compared by Student's t-test (two tailed). P values for significance were set at 0.05, unless otherwise stated. All analysis was performed using Graphpad Prism Software (Version 5 for Windows).
Supporting Information S1 Fig. siRNA successfully knocks down expression of targeted genes. A549 cells were transfected with siRNA against LIF and NEK7 at 50 nM for 48 h. Cells were infected with A/Ca (H1N1) at MOI 0.1. RNA was extracted for gene expression analysis of A) LIF and B) NEK7 using RT-qPCR. Expression is normalized to 18S and relative to non-infected cells. Data are from 3 replicate wells ± SEM. Ã p<0.05, ÃÃÃ p<0.001. (TIFF)